Mitchell & Pahl Private Wealth LLC Buys 292 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Mitchell & Pahl Private Wealth LLC grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,603 shares of the medical research company’s stock after purchasing an additional 292 shares during the quarter. Mitchell & Pahl Private Wealth LLC’s holdings in Charles River Laboratories International were worth $665,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CRL. Kera Capital Partners Inc. bought a new position in Charles River Laboratories International during the fourth quarter worth $246,000. Pinnacle Bancorp Inc. grew its holdings in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares during the period. Fiduciary Financial Group LLC raised its position in shares of Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after acquiring an additional 63 shares in the last quarter. Czech National Bank lifted its stake in shares of Charles River Laboratories International by 5.4% in the 4th quarter. Czech National Bank now owns 11,088 shares of the medical research company’s stock valued at $2,047,000 after purchasing an additional 571 shares during the period. Finally, ORG Wealth Partners LLC bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $56,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CRL. Redburn Atlantic began coverage on Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price for the company. UBS Group reiterated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday. Bank of America cut their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research note on Monday, November 18th. Finally, Citigroup lowered shares of Charles River Laboratories International from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $215.00 to $175.00 in a report on Tuesday, October 1st. Three analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $209.00.

Charles River Laboratories International Trading Down 1.2 %

Shares of Charles River Laboratories International stock opened at $163.77 on Tuesday. The company has a market capitalization of $8.37 billion, a P/E ratio of 20.50, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38. The stock has a fifty day simple moving average of $189.50 and a 200 day simple moving average of $198.14. Charles River Laboratories International, Inc. has a 12-month low of $160.85 and a 12-month high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same quarter in the prior year, the business posted $2.72 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).